Efficacy of Pembrolizumab Combined with Pemetrexed and Carboplatin in the Treatment of Advanced Non Squamous Non-small Cell Lung Cancer and Its Effects on Tumor Markers and Cellular Immune Function
Objective:To explore the effiicacy of carboplatin and pemetrexed combined with pablizumab in the treatment of advanced non squamous non-small cell lung cancer(NSCLC)and its effects on cellular immune function and tumor markers.Methods:78 patients with advanced non squamous NSCLC who were admitted to the Affiliated Hospital of Xuzhou Medical University from October 2018 to February 2021 were selected,they were divide into control group(n=39,received pemetrexed combined with carboplatin treat-ment)and combined group(n=39,received pembrolizumab treatment on the basis of control group)according to the random number table method.The efficacy,tumor marker levels,cellular immune function indicators,incidence of adverse reactions.Results:The objective re-sponse rate and disease control rate of combined group were higher than those of control group(P＜0.05).There was no statistically signif-icant difference in the incidence of adverse reactions between two groups(P＞0.05).After treatment,the carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),and carbohydrate antigen 125(CA125)levels decreased of two groups,and combined group were lower than those of control group(P＜0.05).After treatment,the CD3+,CD4+,and CD4+/CD8+decreased of two groups,but com-bined group were higher than those of control group(P＜0.05).After treatment,the CD8+increased of two groups,but combined group was lower than that of control group(P＜0.05).Conclusion:Pabolizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous NSCLC can effectively control disease progression,improve patient immune function,and reduce CEA,CYFRA21-1,and CA125 levels.
Non squamous non-small cell lung cancerPembrolizumabPemetrexedCarboplatinEfficacyTumor markersIm-mune function
NETL
NSTL
万方数据
